A cognitive behavioral therapy program delivered by smartphone app improved the mental health and quality of life of people ...

Treatment with envudeucitinib was safe and effective through 52 weeks among patients with with moderate to severe plaque psoriasis.

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update DMC Confirms No Safety Concerns for Ongoing Phase 3 FLASH2 Trial On ...

Umbilical cord-derived mesenchymal stromal cells could provide clinical benefit in patients with severe, treatment-resistant ...

Significant rates of depression, anxiety, and sleep disturbances in patients with psoriatic arthritis (PsA) and palmoplantar psoriasis (PPP) were identified, underscoring the need for integrated ...

Phase 4 results from the UnlIMMited trial show that risankizumab significantly improves psoriasis (PsO) symptoms in the ...

Once-daily, steroid-free topical foam intentionally formulated to help manage psoriasis across difficult-to-treat areas of ...

Almond oil offers remarkable benefits for skin and hair, acting as a natural powerhouse for nourishment and protection. Its gentle, hypoallergenic pro ...

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic ...

An update from Arctic Bioscience AS ( ($DE:9TD) ) is now available. Arctic Bioscience reported significant advancements in its pharmaceutical and ...

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical ...